Jane Street’s Lexeo Therapeutics LXEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-140,096
Closed -$993K 12397
2025
Q4
$1.39M Buy
140,096
+10,624
+8% +$96.9K ﹤0.01% 5470
2025
Q3
$860K Buy
+129,472
New +$626K ﹤0.01% 6647
2025
Q1
Sell
-14,512
Closed -$95.5K 10122
2024
Q4
$95.5K Sell
14,512
-21,165
-59% -$167K ﹤0.01% 8779
2024
Q3
$323K Buy
35,677
+8,918
+33% +$106K ﹤0.01% 7914
2024
Q2
$429K Sell
26,759
-13,174
-33% -$191K ﹤0.01% 7262
2024
Q1
$626K Buy
39,933
+973
+2% +$15.2K ﹤0.01% 6260
2023
Q4
$523K Buy
+38,960
New +$484K ﹤0.01% 6682

Other funds holding LXEO

Jane Street's LXEO Position: Q1 2026 in Review

Jane Street sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 140,096 shares — an estimated $993K sold.

Jane Street first reported a position in LXEO in Q4 2023 and held it in 7 quarters. The position peaked at $1.39M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Jane Street reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 140,096 Lexeo Therapeutics shares in Q1 2026, an estimated $993K.
  • Jane Street first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 7 quarters.
  • Jane Street's Lexeo Therapeutics position peaked at $1.39M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.